Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies

British Journal of Clinical Pharmacology

Volumn 83, Issue 4, 2017, Pages 909-922

  Shen, Zi Qi ^a   Gao, Shan Yan ^a   Li, Shawn Xiang ^a   Zhang, Tie Ning ^a   Liu, Cai Xia ^a   Lv, Hai Chen ^b   Zhang, Yuan ^a   Gong, Ting Ting ^a   Xu, Xin ^a   Ji, Chao ^a   Wu, Qi Jun ^a   Li, Da ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

antidepressive agents; cohort studies; congenital anomalies; meta analysis; pregnancy; sertraline

Indexed keywords

SERTRALINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CARDIOVASCULAR MALFORMATION; COHORT ANALYSIS; CONGENITAL MALFORMATION; DIGESTIVE SYSTEM MALFORMATION; DRUG USE; EAR MALFORMATION; EYE MALFORMATION; FACE MALFORMATION; FEMALE; FIRST TRIMESTER PREGNANCY; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; META ANALYSIS; MUSCULOSKELETAL SYSTEM MALFORMATION; NECK MALFORMATION; NERVOUS SYSTEM MALFORMATION; PREGNANCY COMPLICATION; PREGNANT WOMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PUERPERAL DEPRESSION; RISK; SYSTEMATIC REVIEW; UROGENITAL TRACT MALFORMATION; DRUG INDUCED MALFORMATION; INFANT; PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; COHORT STUDIES; FEMALE; HUMANS; INFANT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RISK; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 85006380524     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13161     Document Type: Article

References (59)

1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 2016; 44: D1054–D1068.
2. Alexander SPH, Fabbro D, Davenport AP, Kelly E, Marrion N, Peters JA, et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 2015; 172: 5744–5869.
3. Ellfolk M, Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol 2010; 30: 249–260.
4. Braithwaite EC, Murphy SE, Ramchandani PG. Effects of prenatal depressive symptoms on maternal and infant cortisol reactivity. Arch Womens Ment Health 2016; 19: 581–590.
5. Davis EP, Glynn LM, Dunkel SC, Hobel C, Chicz-Demet A, Sandman CA. Corticotropin-releasing hormone during pregnancy is associated with infant temperament. Dev Neurosci 2005; 27: 299–305.
6. Li D, Liu L, Odouli R. Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. Hum Reprod 2009; 24: 146–153.
7. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055–2061.
8. Diav-Citrin O, Ornoy A. Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat? Obstet Gynecol Int 2012; 2012: 698947.
9. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008; 198: 191–194.
10. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van DBL, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006; 62: 863–870.
11. Kieler H. The Nordic health registers – an important source when evaluating the safety of antidepressants during pregnancy. Clin Epidemiol 2010; 2: 205–207.
12. El MH, Jaddoe VW, Hudziak JJ, Roza SJ, Steegers EA, Hofman A, et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 2012; 69: 706–714.
13. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Andersen NL, Torp-Pedersen C, et al. Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study. PLoS One 2013; 8: e63034.
14. Ramos E, Oraichi D, Rey E, Blais L, Berard A. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG 2007; 114: 1055–1064.
15. Sadler TW. Selective serotonin reuptake inhibitors (SSRIs) and heart defects: potential mechanisms for the observed associations. Reprod Toxicol 2011; 32: 484–489.
16. Sari Y, Zhou FC. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neurosci 2003; 21: 417–424.
17. Huybrechts KF, Hernandez-Diaz S, Avorn J. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014; 371: 1168–1169.
18. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, Afzal S, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012; 2: e001148.
19. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010; 2: 29–36.
20. Merlob P, Birk E, Sirota L, Linder N, Berant M, Stahl B, et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 2009; 85: 837–841.
21. Berard A, Zhao JP, Sheehy O. Sertraline use during pregnancy and the risk of major malformations. Am J Obstet Gynecol 2015; 212: 791–795.
22. Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ 2015; 350: h1798.
23. Ban L, Gibson JE, West J, Fiaschi L, Sokal R, Smeeth L, et al. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. BJOG 2014; 121: 1471–1481.
24. Nordeng H, van Gelder MM, Spigset O, Koren G, Einarson A, Eberhard-Gran M. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2012; 32: 186–194.
25. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011; 91: 142–152.
26. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011; 118: 111–120.
27. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008; 83: 68–76.
28. Kallen BA, Otterblad OP. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007; 79: 301–308.
29. Wang S, Yang L, Wang L, Gao L, Xu B, Xiong Y. Selective serotonin reuptake inhibitors (SSRIs) and the risk of congenital heart defects: a meta-analysis of prospective cohort studies. J Am Heart Assoc 2015; 4.
30. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–2012.
31. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264–269, W64.
32. Wells G, Shea B, O'Connel D. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. 2013. Available at http://www.ohri.ca/programs/clinical_epidemiological/oxford.asp (last accessed 14 October 2016).
33. Hamling J, Lee P, Weitkunat R, Ambuhl M. Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med 2008; 27: 954–970.
34. Luan NN, Wu QJ, Gong TT, Vogtmann E, Wang YL, Lin B. Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies. Am J Clin Nutr 2013; 98: 1020–1031.
35. Gong TT, Wu QJ, Wang YL, Ma XX. Circulating adiponectin, leptin and adiponectin-leptin ratio and endometrial cancer risk: Evidence from a meta-analysis of epidemiologic studies. Int J Cancer 2015; 137: 1967–1978.
36. Wu QJ, Wu L, Zheng LQ, Xu X, Ji C, Gong TT. Consumption of fruit and vegetables reduces risk of pancreatic cancer: evidence from epidemiological studies. Eur J Cancer Prev 2016; 25: 196–205.
37. Luan NN, Wu L, Gong TT, Wang YL, Lin B, Wu QJ. Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: a meta-analysis of epidemiological studies. Cancer Causes Control 2015; 26: 65–78.
38. Chen J, Gong TT, Wu QJ. Parity and gastric cancer risk: a systematic review and dose–response meta-analysis of prospective cohort studies. Sci Rep 2016; 6: 18766.
39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
40. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
41. Jiao YS, Gong TT, Wang YL, Wu QJ. Comorbidity and survival among women with ovarian cancer: evidence from prospective studies. Sci Rep 2015; 5: 11720.
42. Wu QJ, Yang Y, Vogtmann E, Wang J, Han LH, Li HL, et al. Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies. Ann Oncol 2013; 24: 1079–1087.
43. Hou R, Wu QJ, Gong TT, Jiang L. Dietary fat and fatty acid intake and epithelial ovarian cancer risk: evidence from epidemiological studies. Oncotarget 2015; 6: 43099–43119.
44. Jiang L, Hou R, Gong TT, Wu QJ. Dietary fat intake and endometrial cancer risk: dose–response meta-analysis of epidemiological studies. Sci Rep 2015; 5: 16693.
45. Wu QJ, Gong TT, Wang YZ. Dietary fatty acids intake and endometrial cancer risk: a dose–response meta-analysis of epidemiological studies. Oncotarget 2015; 6: 36081–36097.
46. Wu QJ, Li YY, Tu C, Zhu J, Qian KQ, Feng TB, et al. Parity and endometrial cancer risk: a meta-analysis of epidemiological studies. Sci Rep 2015; 5: 14243.
47. Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. Int J Cancer 2013; 132: 2894–2900.
48. Wei J, Liu CX, Gong TT, Wu QJ, Wu L. Cigarette smoking during pregnancy and preeclampsia risk: a systematic review and meta-analysis of prospective studies. Oncotarget 2015; 6: 43667–43678.
49. Wu QJ, Xie L, Zheng W, Vogtmann E, Li HL, Yang G, et al. Cruciferous vegetables consumption and the risk of female lung cancer: a prospective study and a meta-analysis. Ann Oncol 2013; 24: 1918–1924.
50. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.
51. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101.
52. Yavarone MS, Shuey DL, Tamir H, Sadler TW, Lauder JM. Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 1993; 47: 573–584.
53. Nebigil CG, Choi DS, Dierich A, Hickel P, Le Meur M, Messaddeq N, et al. Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci U S A 2000; 97: 9508–9513.
54. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 2003; 4: 1002–1012.
55. Dai SQ, Yu LP, Shi X, Wu H, Shao P, Yin GY, et al. Serotonin regulates osteoblast proliferation and function in vitro. Braz J Med Biol Res 2014; 47: 759–765.
56. Mawe GM, Hoffman JM. Serotonin signalling in the gut – functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 2013; 10: 473–486.
57. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007; 29: 918–926.
58. De Jong VDBL, Feenstra N, Sorensen HT, Cornel MC. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. Teratology 1999; 60: 33–36.
59. Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, et al. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007; 115: 2995–3014.